Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR29022840

— · A

c03b92c1-268f-5dcb-98bf-7d1d6b500934

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
  • ANGIOGENESIS+0.450
  • IL6_JAK_STAT3_SIGNALING+0.410
  • ALLOGRAFT_REJECTION+0.400
  • INTERFERON_GAMMA_RESPONSE+0.390
  • COMPLEMENT+0.360
  • INFLAMMATORY_RESPONSE+0.360
  • UV_RESPONSE_DN+0.330
  • INTERFERON_ALPHA_RESPONSE+0.320
  • KRAS_SIGNALING_UP+0.300

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.400
  • ADIPOGENESIS-0.280
  • MYC_TARGETS_V2-0.270
  • E2F_TARGETS-0.260
  • CHOLESTEROL_HOMEOSTASIS-0.230
  • G2M_CHECKPOINT-0.230
  • DNA_REPAIR-0.190
  • HEME_METABOLISM-0.190
  • FATTY_ACID_METABOLISM-0.170
  • PEROXISOME-0.150

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-XF-AAN4-01A-11R-A42T-07
bladder-landscape@3
——0.901
2c277dab0-361f-4aa6-96b1-522a6e556ae1
colon-landscapes@1
——0.896
3TCGA-D8-A141-01A-11R-A115-07
breast-umap@18
—A0.896
4ERR2208918
melanoma-umap@29
——0.893
5TCGA-BH-A6R9-01A-21R-A32P-07
breast-umap@18
—A0.893
6cadbc884-10b6-41e4-8aee-dc11a1453b8c
colon-landscapes@1
——0.890
7f22cfa82-a346-4fed-bc81-21a29bf990ee
colon-landscapes@1
——0.883
8SRR8613717
breast-umap@18
—D0.881
9TCGA-AN-A0FN-01A-11R-A034-07
breast-umap@18
—A0.880
10SRR8613789
breast-umap@18
—A0.878

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 26 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.490Inavolisib— uncovered
ANGIOGENESIS0.450Remibrutinib— uncovered
IL6_JAK_STAT3_SIGNALING0.410Inavolisib— uncovered
ALLOGRAFT_REJECTION0.400Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.390Idelalisib— uncovered
COMPLEMENT0.360Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.360Idelalisib— uncovered
UV_RESPONSE_DN0.330Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.320Inavolisib— uncovered
KRAS_SIGNALING_UP0.300Inavolisib— uncovered
HEDGEHOG_SIGNALING0.280Inavolisib— uncovered
APICAL_JUNCTION0.240Inavolisib— uncovered
PANCREAS_BETA_CELLS0.240Cobimetinib— uncovered
TGF_BETA_SIGNALING0.240Inavolisib— uncovered
COAGULATION0.230Binimetinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.230Inavolisib— uncovered
IL2_STAT5_SIGNALING0.220Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.220Inavolisib— uncovered
APICAL_SURFACE0.190Temsirolimus— uncovered
MYOGENESIS0.140Inavolisib— uncovered